Evaluation of anti-arthritic activity of tofacitinib citrate controlled released formulation in complete Freund's adjuvant induced arthritis experimental model

In an animal model of complete Freund's adjuvant-induced arthritis, the tofacitinib citrate controlled-release formulation (TCRF) was examined. We examined the impact of TCRF on FCA-induced arthritis in rats, as well as weight alterations and changes in haematological and biochemical indicators. In contrast to the control group, the paw volume reduced and the animals' overall weight increased normally in the TCRF-treated animals, despite the fact that their body weight increased in the FCA-induced arthritis rats. An effective treatment for arthritis-induced haematological and biochemical abnormalities in arthritic rats was found to be TCRF at doses of 2.5, 5, 7, and 10mg/kg/p.o. At both the early and late stages of FCA-induced arthritis, the effects of treating arthritis-prone rats with TCRF showed significant reductions in rat paw edoema volume as well as a restoration of normal haematological and biochemical parameters